SynWeave™: Redefining Cell Line Development For Next-Generation Biologics

An integrated approach to cell line development and upstream optimization is reshaping how biologics are advanced into manufacturing. By using transposon-based, semi-targeted gene integration, this strategy helps overcome traditional challenges such as positional effects, which often lead to variable expression and low integration efficiency.

Because most cells receive complete, functional constructs, clone-to-clone variability is reduced, and the need for extensive screening is minimized. This allows earlier alignment between clone selection and a robust upstream process, speeding up the identification of stable, high-producing clones while preserving critical quality attributes.

High-throughput bioreactor systems, combined with Design of Experiments (DoE) and Quality by Design (QbD) principles, enable rapid, data-driven optimization of media, feeding strategies, and process parameters. Real-time monitoring further supports consistent performance, process understanding, and regulatory readiness, while well-defined design spaces ensure smooth scalability from development through manufacturing.

Overall, this integrated methodology delivers higher productivity, shorter development timelines, and greater flexibility across monoclonal antibodies, biosimilars, bispecifics, and other recombinant proteins — offering a more predictable and efficient path to modern biopharmaceutical manufacturing.